Dr. Carlos González Núñez (Mexico City) reviews exciting SABCS 2025 advances for HR+/HER2- metastatic breast cancer, focusing on options after CDK4/6 inhibitor progression. He highlights phase 2 SUMMIT data with samuraciclib plus fulvestrant, showing promising PFS and a manageable safety profile.
